Overview
GM2 gangliosidosis, AB variant is an extremely rare inherited metabolic disease that affects the brain and nervous system. It is also sometimes called the GM2 activator deficiency or Tay-Sachs AB variant. In this condition, the body cannot properly break down a fatty substance called GM2 ganglioside, which builds up in nerve cells of the brain. Unlike the more well-known Tay-Sachs disease and Sandhoff disease (which are caused by problems with the enzymes themselves), the AB variant is caused by a missing or defective activator protein that the enzymes need to do their job. Without this activator protein, the GM2 ganglioside accumulates and progressively destroys nerve cells. The disease most commonly appears in infancy, usually between 3 and 6 months of age. Affected babies may initially develop normally but then begin to lose skills they had already learned, such as sitting, crawling, or babbling. Common symptoms include an exaggerated startle response to loud noises, progressive weakness, loss of vision, seizures, and severe intellectual disability. As the disease progresses, children lose the ability to move, swallow, and interact with their surroundings. Unfortunately, there is currently no cure or disease-modifying treatment for the AB variant of GM2 gangliosidosis. Care is focused on managing symptoms and keeping the child as comfortable as possible. This includes seizure management, nutritional support, respiratory care, and physical therapy. Research into potential therapies such as gene therapy and substrate reduction therapy is ongoing but remains in early stages.
Also known as:
Key symptoms:
Exaggerated startle response to loud soundsLoss of previously learned skills (developmental regression)Progressive muscle weaknessDifficulty swallowingSeizuresVision loss leading to blindnessCherry-red spot on the back of the eyeIncreasing stiffness or spasticity of musclesLoss of ability to sit, crawl, or moveIntellectual disabilityEnlarged head (macrocephaly) in some casesDecreased responsiveness to surroundingsFeeding difficultiesBreathing problems
Clinical phenotype terms (25)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for GM2 gangliosidosis, AB variant.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for GM2 gangliosidosis, AB variant at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to GM2 gangliosidosis, AB variant.
Community
No community posts yet. Be the first to share your experience with GM2 gangliosidosis, AB variant.
Start the conversation →Latest news about GM2 gangliosidosis, AB variant
No recent news articles for GM2 gangliosidosis, AB variant.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.How can we confirm that this is the AB variant specifically, and not Tay-Sachs or Sandhoff disease?,What symptoms should we expect to see next, and how can we prepare for them?,What is the best plan for managing seizures and feeding difficulties?,Are there any clinical trials or experimental treatments that our child might be eligible for?,Should other family members or future pregnancies be tested, and how does carrier testing work for this condition?,What palliative care and support services are available to help our family?,Can you connect us with other families affected by GM2 gangliosidosis for peer support?
Common questions about GM2 gangliosidosis, AB variant
What is GM2 gangliosidosis, AB variant?
GM2 gangliosidosis, AB variant is an extremely rare inherited metabolic disease that affects the brain and nervous system. It is also sometimes called the GM2 activator deficiency or Tay-Sachs AB variant. In this condition, the body cannot properly break down a fatty substance called GM2 ganglioside, which builds up in nerve cells of the brain. Unlike the more well-known Tay-Sachs disease and Sandhoff disease (which are caused by problems with the enzymes themselves), the AB variant is caused by a missing or defective activator protein that the enzymes need to do their job. Without this activa
How is GM2 gangliosidosis, AB variant inherited?
GM2 gangliosidosis, AB variant follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does GM2 gangliosidosis, AB variant typically begin?
Typical onset of GM2 gangliosidosis, AB variant is infantile. Age of onset can vary across affected individuals.
Which specialists treat GM2 gangliosidosis, AB variant?
1 specialists and care centers treating GM2 gangliosidosis, AB variant are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.